Coronavirus company news summary – Thermo Fisher launches new TaqPath kit to identify viral mutations – FluroTest says saliva-based test system now operational
Thermo Fisher Scientific has introduced the TaqPath COVID-19 RNase P 2.0 kit, which holds the CE-IVD Mark, to detect existing and future mutations of the SARS-CoV-2 virus. The company redesigned the test to identify active infections by spotting the presence of any one of eight SARS-CoV-2 gene targets in nasopharyngeal and nasal swab specimens. It is expected to deliver precise results even after mutations occur.
FluroTech has announced that its novel saliva-based point of access test system and immunoassay to detect SARS-CoV-2 is now fully operational. The new pandemic response platform includes kits to collect saliva, agents to deactivate the virus, the robotic, automated test processing platform and the software that runs it. It also comes with the immunoassay to process saliva samples and the microplate reader to analyse the presence SARS-CoV-2 within the samples. The company is now focusing on commercial product optimisation.
Affinity Empowering has enrolled the University of Arkansas for Medical Sciences (UAMS) Gap Services programme in Operation Expanded Testing (OET), a US Government initiative that offers surveillance polymerase chain reaction (PCR) testing to schools and community organisations to protect against Covid-19. Affinity Empowering provides the OET initiative on behalf of Eurofins Clinical. As part of OET, the UAMS programme is now offering free Covid-19 testing in Arkansas. The initiative uses a PCR test that can identify Covid-19 in the earliest stages when viral load is low, Affinity said.